haia_8ka.htm0001848861true00018488612023-07-052023-07-050001848861haia:ClassAOrdinaryShareUnitsMember2023-07-052023-07-050001848861haia:ClassAOrdinarystockMember2023-07-052023-07-050001848861haia:ClassAOrdinarySharesWarrantsMember2023-07-052023-07-05iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K/A
(Amendment No. 1)
CURRENT REPORT
PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of Report (Date of earliest event reported): July 14, 2023(July 5, 2023)
HEALTHCARE AI ACQUISITION CORP. |
(Exact name of registrant as specified in its charter) |
Cayman Islands | | 001-41145 | | 98-1585450 |
(State or other jurisdiction of incorporation) | | (Commission File Number) | | (IRS Employer Identification No.) |
8 The Green, Ste 15614
Dover DE 19901
(Address of principal executive offices, including zip code)
(917) 446-0469
Registrant’s telephone number, including area code:
Not Applicable
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
| ☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) |
| | |
| ☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) |
| | |
| ☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c)) |
Securities registered pursuant to Section 12(b) of the Act:
Title of each class | | Trading Symbol(s) | | Name of each exchange on which registered |
Units, each consisting of one Class A Ordinary Share and one-half of one Redeemable Warrant | | HAIAU | | The Nasdaq Stock Market, LLC |
| | | | |
Class A Ordinary Share, par value $0.0001 per share | | HAIA | | The Nasdaq Stock Market, LLC |
| | | | |
Warrant, each whole warrant exercisable for one Class A Ordinary Share for $11.50 per share | | HAIAW | | The Nasdaq Stock Market, LLC |
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company ☒
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Explanatory Note
On July 11, 2023, Healthcare AI Acquisition Corp. (the “Company”), filed a Current Report on Form 8-K (the “Original Report”) reporting the change in the Company’s certifying accountant. This Current Report on Form 8-K/A amends and restates the Original Report in order to supplement information previously disclosed, and to include Exhibit 16.1, the Letter from Marcum LLP regarding the change in the Registrant’s certifying accountant. The entire Current Report on Form 8-K is being filed as amended and restated to include this supplemental information and to reflect the inclusion of this exhibit.
Item 4.01 Changes in Registrant’s Certifying Accountant.
a) Dismissal of Independent Registered Public Accounting Firm.
On July 5, 2023, upon the approval of its Audit Committee of the Board of Directors (the “Audit Committee”) of Healthcare AI Acquisition Corp. (the “Company”), the Company dismissed Marcum LLP (“Marcum”) as the Company’s independent registered public accounting firm.
Marcum audited the financial statements of the Company for each of the year ended December 31, 2021 and 2022. The report of Marcum on such financial statements did not contain an adverse opinion or disclaimer of opinion and was not qualified or modified as to uncertainty, audit scope or accounting principles. Their financial statements contained an explanatory paragraph relating to substantial doubt about the ability of the Company to continue as a going concern as described in Note 1 to the financial statements.
During the fiscal year ended December 31, 2022 and the subsequent interim periods through the date of dismissal, there have been no: (i) “disagreements” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) with Marcum on any matter of accounting principles or practices, financial statement disclosure, or auditing scope or procedure, which disagreement, if not resolved to the satisfaction of Marcum, would have caused them to make reference thereto in their report on the financial statements or (ii) “reportable events” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K), other than the material weaknesses in internal controls identified by management related to analyzing complex financial instruments, specifically the valuation of warrant liabilities, and recording of accounts payable and accrued expenses that is disclosed in the Company's Form 10-K and Form 10-Qs filed with the SEC on April 21, 2022 and March 31, 2023 and May 23, 2022, August 10, 2022, November 11, 2022, and May 19, 2023, respectively.
The Company has provided Marcum a copy of the disclosure made in response to this Item 4.01 and Marcum has confirmed their agreement with the disclosure contained herein.
(b) Newly Appointed Independent Registered Public Accountant
On July 11, 2023, upon the approval of the Audit Committee, the Company engaged BF Borgers CPA PC (“Borgers”) as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, effective immediately.
During the fiscal year ended December 31, 2022 and the subsequent interim periods through the date of Borgers’ engagement, neither the Company nor anyone acting on its behalf consulted Borgers regarding either (i) the application of accounting principles to a specified transaction, either completed or proposed, or the type of audit opinion that might be rendered on the Company's consolidated financial statements and neither a written report nor oral advice was provided to the Company by Borgers that Borgers concluded was an important factor considered by the Company in reaching a decision as to such accounting, auditing, or financial reporting issue; or (ii) any matter that was either the subject of a “disagreement” (as that term is defined in Item 304(a)(1)(iv) of Regulation S-K and the related instructions) or a “reportable event” (as that term is defined in Item 304(a)(1)(v) of Regulation S-K).
Item 9.01. Financial Statements and Exhibits.
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
| HEALTHCARE AI ACQUISITION CORP. | |
| | | |
Dated: July 14, 2023 | By: | /s/ Zikang Wu | |
| Name: | Zikang Wu | |
| Title: | Chief Executive Officer | |
